REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day REGN SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
-9.3%
8/1/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
-0.2%
5/2/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
7.0%
2/2/2024
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
-3.5%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/17 Regeneron Announces Important Advances in Novel COVID-19 Antibody Program 7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
Top News Decliners
3/19 Coronavirus Proves Drug Companies To Be Innovators [Forbes] -10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
REGN
SPY
QQQ
SPX
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
REGN SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
11/22
10:09 am
regn
Low
BioFuture™ 2024 Wraps Up: Hundreds of High-Profile Attendees Joined Record Numbers of Investors and Media [Yahoo! Finance]
11/21
01:30 pm
regn
Low
Vyriad signs 'huge' deal with Novartis to develop new cancer treatments [Yahoo! Finance]
11/19
10:27 am
regn
Low
Here's Why Regeneron Pharmaceuticals (REGN) Declined in Q3 [Yahoo! Finance]
11/16
06:05 am
regn
Low
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/15
08:04 am
regn
Medium
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.
11/15
06:03 am
regn
Medium
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Citigroup Inc. to a "hold" rating.
11/15
01:17 am
regn
Low
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) [Yahoo! Finance]
11/15
12:59 am
regn
Low
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
11/14
08:09 am
regn
Low
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.
10/31/2024
06:30 am
regn
-9.3%
BEAT
8/1/2024
06:30 am
regn
-0.2%
BEAT
5/2/2024
06:30 am
regn
7.0%
BEAT
2/2/2024
06:30 am
regn
-3.5%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
11/16
06:05 am
Upgrades
Strong-Buy
Wolfe Research
Low
0.1%
11/16
06:05 am
Upgrades
Strong-Buy
Wolfe Research
Low
0.1%
11/15
08:04 am
Initiates
Outperform
Wolfe Research
Medium
-3.3%
11/15
08:04 am
Initiates
Outperform
Wolfe Research
Medium
-3.3%
11/15
06:03 am
Upgrades
Hold
Citigroup Inc.
Medium
-3.6%
11/15
05:56 am
Initiates
Outperform
Wolfe Research
Medium
-3.6%
11/15
05:56 am
Initiates
Outperform
Wolfe Research
Medium
-3.6%
11/14
04:16 pm
Initiates
VIEW
WOLFE RESEARCH
Medium
-3.3%
11/14
04:16 pm
Initiates
VIEW
WOLFE RESEARCH
Medium
-3.3%
11/12
04:04 pm
regn
Low
Form 4 REGENERON PHARMACEUTICAL For: Nov 08 Filed by: MURPHY ANDREW J
11/5
04:23 pm
regn
Low
Form 4 REGENERON PHARMACEUTICAL For: Nov 01 Filed by: McCourt Marion
11/1
04:38 pm
regn
Low
Form 144 REGENERON PHARMACEUTICAL Filed by: McCourt Marion
10/31
04:34 pm
regn
Low
Form S-3ASR REGENERON PHARMACEUTICAL
10/31
07:17 am
regn
Medium
Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30
10/31
07:11 am
regn
Medium
Form 8-K REGENERON PHARMACEUTICAL For: Oct 31
10/7
07:00 am
regn
Low
Form 8-K REGENERON PHARMACEUTICAL For: Oct 07
10/3
04:02 pm
regn
Low
Form 4 REGENERON PHARMACEUTICAL For: Oct 01 Filed by: McCourt Marion
10/3
04:02 pm
regn
Low
Form 4 REGENERON PHARMACEUTICAL For: Oct 01 Filed by: RYAN ARTHUR F
Show more
Top News Gainers
3/17 Regeneron Announces Important Advances in Novel COVID-19 Antibody Program 7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
Top News Decliners
3/19 Coronavirus Proves Drug Companies To Be Innovators [Forbes] -10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%